[Federal Register Volume 64, Number 194 (Thursday, October 7, 1999)]
[Rules and Regulations]
[Pages 54520-54522]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-26215]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Bureau of Export Administration
15 CFR Part 774
[Docket No. 990920257-9257-01]
RIN 0694-AB85
Revisions to the Commerce Control List (ECCNs 1C351, 1C991, and
2B351): Medical Products Containing Biological Toxins; and Toxic Gas
Monitoring Systems and Dedicated Detectors
AGENCY: Bureau of Export Administration, Commerce.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: This final rule amends the Commerce Control List (CCL) of the
Export Administration Regulations to implement an October 1998
Australia Group agreement to amend controls on toxic gas monitoring
systems and dedicated detectors. This final rule also amends the CCL to
authorize, without a license, exports of medical products containing
controlled biological toxins (except saxitoxin and ricin) that are
developed, packaged and sold for medical treatment. This rule will
result in a decreased licensing burden on U.S. industry.
EFFECTIVE DATE: This rule is effective October 7, 1999.:
FOR FURTHER INFORMATION CONTACT: James Seevaratnam, Director, Chemical
and Biological Controls Division, Bureau of Export Administration,
(202) 501-7900.
SUPPLEMENTARY INFORMATION:
Background
The Australia Group (AG), a multilateral forum for the coordination
of export controls to curtail the proliferation of chemical and
biological weapons, held its annual consultations in Paris, October 9-
15, 1998. The 30 AG member countries agreed to maintain export controls
on a list of chemicals,
[[Page 54521]]
biological agents, relevant equipment and technology that could be used
in the production of chemical or biological weapons. The AG reviews
items on its control list periodically to enhance the effectiveness and
achieve greater harmonization of member governments' national controls.
At the October 1998 Australia Group consultations, participants
agreed to revise the control list entry for toxic gas monitoring
systems and dedicated detectors to clarify the scope of controls. To
implement this agreement, this final rule amends the Commerce Control
List (CCL) of the Export Administration Regulations (EAR) by revising
Export Control Classification Number (ECCN) 2B351. Specifically, the
phrase ``or organic compounds containing phosphorus, sulphur, fluorine
or chlorine'' is deleted from the description of items controlled, and
a technical note is added to clarify that systems capable of detecting
compounds containing these chemicals are controlled. The Department of
Commerce has routinely interpreted this entry to include systems with
capability to detect inorganic compounds. The AG discussions confirmed
that other AG members agreed with this interpretation.
The Department of Commerce also maintains controls on exports of
biological agents that could be used in the production of biological
weapons. These materials require a license for export and reexport to
all destinations, except Canada. These controls are implemented in
accordance with the export control provisions of the Australia Group.
Medical products that contain the AG-controlled biological toxins that
are prepackaged in units applicable to the intended medical treatment
pose no significant proliferation concerns. Therefore, this final rule
adds to ECCN 1C991 medical products that contain biological toxins
controlled under ECCN 1C351.d, except d.5 and d.6 (ricin and
saxitoxin), when such products are developed, packaged and sold for
medical treatment. Such products may be exported and reexported without
a license to all countries except countries listed in CB Column 3 on
the Commerce Country Chart (Supplement No. 1 to part 738 of the EAR).
This new exemption from licensing requirements does not apply if the
biological toxin is to be exported in any other configuration,
including bulk shipments, or for any other end-uses.
Although the Export Administration Act (EAA) expired on August 20,
1994, the President invoked the International Emergency Economic Powers
Act and continued in effect the EAR, and, to the extent permitted by
law, the provisions of the EAA in Executive Order 12924 of August 19,
1994, extended by Presidential notice of August 10, 1999, 64 FR 44101
(August 13, 1999).
Rulemaking Requirements
1. This final rule has been determined to be not significant for
purposes of E.O. 12866.
2. Notwithstanding any other provision of law, no person is
required to respond to, nor shall any person be subject to a penalty
for failure to comply with a collection of information, subject to the
requirements of the Paperwork Reduction Act, unless that collection of
information displays a currently valid Office of Management and Budget
Control Number. This rule involves a collection of information subject
to the Paperwork Reduction Act of 1980 (44 U.S.C. 3501 et seq.). This
collection has been approved by the Office of Management and Budget
under control numbers 0694-0088, ``Multi-Purpose Application,'' which
carries a burden hour estimate of 45 minutes for a manual submission
and 40 minutes for an electronic submission.
3. This rule does not contain policies with Federalism implications
sufficient to warrant preparation of a Federalism assessment under E.O.
12612.
4. The provisions of the Administrative Procedure Act (5 U.S.C.
553) requiring notice of proposed rulemaking, the opportunity for
public participation, and a delay in effective date, are inapplicable
because this regulation involves a military and foreign affairs
function of the United States (Sec. 5 U.S.C. 553(a)(1)). Further, no
other law requires that a notice of proposed rulemaking and an
opportunity for public comment be given for this interim final rule.
Because a notice of proposed rulemaking and an opportunity for public
comment are not required to be given for this rule under 5 U.S.C. or by
any other law, the requirements of the Regulatory Flexibility Act (5
U.S.C. 601 et seq. ) are not applicable.
List of Subjects in 15 CFR Part 774
Exports, foreign trade.
Accordingly, 15 CFR Chapter 7, Subchapter C, is amended to read as
follows:
1. The authority citation for 15 CFR part 774 continues to read as
follows:
Authority: 50 U.S.C. app. 2401 et seq.; 50 U.S.C. 1701 et seq.;
10 U.S.C. 7420; 10 U.S.C. 7430(e); 18 U.S.C. 2510 et seq.; 22 U.S.C.
287c, 22 U.S.C. 3201 et seq., 22 U.S.C. 6004; 30 U.S.C. 185(s),
185(u); 42 U.S.C. 2139a; 42 U.S.C. 6212; 43 U.S.C. 1354; 46 U.S.C.
app. 466c; 50 U.S.C. app. 5; E.O. 12924, 59 FR 43437, 3 CFR, 1994
Comp., p. 917; E.O. 13026, 61 FR 58767, 3 CFR, 1996 Comp., p. 228;
Notice of August 10, 1999, 64 FR 44101 (August 13, 1999).
PART 774--[AMENDED]
2. Category 1, Materials, of the Commerce Control List is amended
by revising the ``List of Items Controlled'' in ECCN 1C351 and revising
ECCN 1C991, to read as follows:
1C351 Human pathogens, zoonoses, and ``toxins'', as follows (see List
of Items Controlled).
* * * * *
List of Items Controlled
Unit: $ value.
Related Controls: All vaccines and ``immunotoxins'' are excluded
from the scope of this entry. Certain medical products that contain
biological toxins controlled under paragraph (d) of this entry, with
the exception of d.5 and d.6, are excluded from the scope of this
entry. Vaccines, ``immunotoxins'', and certain medical products
excluded from the scope of this entry are controlled under ECCN 1C991.
Related Definition: 1.) For the purposes of this entry
``immunotoxin'' is defined as an antibody-toxin conjugate intended to
destroy specific target cells (e.g., tumor cells) that bear antigens
homologous to the antibody. 2.) For the purposes of this entry
``subunit'' is defined as a portion of the ``toxin''.
Items: a. Viruses, as follows:
a.1. Chikungunya virus;
a.2. Congo-Crimean haemorrhagic fever virus;
a.3. Dengue fever virus;
a.4. Eastern equine encephalitis virus;
a.5. Ebola virus;
a.6. Hantaan virus;
a.7. Japanese encephalitis virus;
a.8. Junin virus;
a.9. Lassa fever virus;
a.10. Lymphocytic choriomeningitis virus;
a.11. Machupo virus;
a.12. Marburg virus;
a.13. Monkey pox virus;
a.14. Rift Valley fever virus;
a.15. Tick-borne encephalitis virus (Russian Spring-Summer encephalitis
virus);
a.16. Variola virus;
a.17. Venezuelan equine encephalitis virus;
a.18. Western equine encephalitis virus;
a.19. White pox; or
a.20. Yellow fever virus.
b. Rickettsiae, as follows:
b.1. Bartonella quintana (Rochalimea quintana, Rickettsia quintana);
b.2. Coxiella burnetii;
b.3. Rickettsia prowasecki; or
[[Page 54522]]
b.4. Rickettsia rickettsii.
c. Bacteria, as follows:
c.1. Bacillus anthracis;
c.2. Brucella abortus;
c.3. Brucella melitensis;
c.4. Brucella suis;
c.5. Burkholderia mallei (Pseudomonas mallei);
c.6. Burkholderia pseudomallei (Pseudomonas pseudomallei);
c.7. Chlamydia psittaci;
c.8. Clostridium botulinum;
c.9. Francisella tularensis;
c.10. Salmonella typhi;
c.11. Shigella dysenteriae;
c.12. Vibrio cholerae; or
c.13. Yersinia pestis.
d. ``Toxins'', as follows: and subunits thereof:
d.1. Botulinum toxins;
d.2. Clostridium perfringens toxins;
d.3. Conotoxin;
d.4. Microcystin (cyanginosin);
d.5. Ricin;
d.6. Saxitoxin;
d.7. Shiga toxin;
d.8. Staphylococcus aureus toxins;
d.9. Tetrodotoxin;
d.10. Verotoxin; or
d.11. Aflatoxins.
1C991 Vaccines, immunotoxins and medical products, as follows (see
List of Items controlled).
License Requirements
Reason for Control: CB, AT.
------------------------------------------------------------------------
Control(s) Country chart
------------------------------------------------------------------------
CB applies to 1C991.c..................... CB Column 3.
AT applies to entire entry................ AT Column 1.
------------------------------------------------------------------------
License Exceptions
LVS: N/A
GBS: N/A
CIV: N/A
List of Items Controlled
Unit: $ value.
Related Controls: N/A.
Related Definitions: For the purpose of this entry ``immunotoxin''
is defined as an antibody-toxin conjugate intended to destroy specific
target cells (e.g., tumor cells) that bear antigens homologous to the
antibody. For the purpose of this entry, ``medical products'' are
prepackaged in units applicable to the intended medical treatment, and
do not include biological toxins in any other configuration, including
bulk shipments, or for any other end-uses. Such toxins are controlled
by ECCN 1C351.
Items: a. Vaccines containing items controlled by ECCNs 1C351,
1C352, 1C353 and 1C354;
b. Immunotoxins; and
c. Medical products containing biological toxins controlled by ECCN
1C351.d, except d.5 and d.6.
3. Category 2, Materials Processing, of the Commerce Control List
is amended by revising the ``List of Items Controlled'' in ECCN 2B351
to read as follows:
2B351 Toxic gas monitoring systems and dedicated detectors
therefor.
* * * * *
List of Items Controlled
Unit: Equipment in number.
Related Controls: N/A.
Related Definitions: N/A.
Items: a. Designed for continuous operation and usable for the
detection of chemical warfare agents or chemicals controlled by 1C350
at concentrations of less than 0.3mg/m \3\ (see technical note below);
or
b. Designed for the detection of cholinesterase-inhibiting
activity.
Technical Note: Toxic Gas Monitoring Systems, controlled under
2B351.a., include those with detection capability for chemicals
containing phosphorus, sulfur, fluorine or chlorine, other than
those specified in 1C350.
Dated: September 30, 1999.
Iain S. Baird,
Deputy Assistant Secretary for Export Administration.
[FR Doc. 99-26215 Filed 10-6-99; 8:45 am]
BILLING CODE 3510-33-P
